immuneACCESS®
English
United States, San Francisco
CLIENTS
数据描述
immuneACCESS® is a dataset for research use only.
clients.adaptivebiotech.com
IP: 40.112.177.176
加载中...
相关论文
7IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial
Lukas Bunse•Katharina Lindner•Antje Wick•Angelika Freitag•Lisa-Marie Lanz等 27 人
Nature Cancer
2026
•2026/7/1
•00 p.1-12
The clonal glioma driver mutation IDH1R132H gives rise to a major histocompatibility class II-restricted neoepitope. A multicenter, first-in-human phase 1 trial met its prespecified primary endpoints by demonstrating safety and immunogenicity of an IDH1-R132H peptide vaccine (IDH1-vac) integrated in...
CancerCNS cancerPeptide vaccinesTumour immunology
10.1038/S43018-026-01199-Y
ISSN:2662-1347
A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2
Yin Qian•Luo Wei•Mallajosyula Vamsee•Bo Yang•Guo Jing等 24 人
Nature Materials
2023
•2023/1/30
•Vol.22 No.3 p.380-390
The ideal vaccine against viruses such as influenza and SARS-CoV-2 must provide a robust, durable and broad immune protection against multiple viral variants. However, antibody responses to current vaccines often lack robust cross-reactivity. Here we describe a polymeric Toll-like receptor 7 agonist...
AdjuvantsDrug delivery
10.1038/S41563-022-01464-2
ISSN:1476-1122
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Creelan Benjamin C.•Wang Chao•Teer Jamie K.•Toloza Eric M.•Yao Jiqiang等 26 人
Nature Medicine
2021
•2021/8/12
•Vol.27 No.8 p.1410-1418
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs administered with nivolumab in 20 patients with...
ImmunotherapyNon-small-cell lung cancerTranslational researchTumour immunology
10.1038/S41591-021-01462-Y
ISSN:1078-8956
Quantifiable blood TCR repertoire components associate with immune aging
Jing Hu•Mingyao Pan•Brett Reid•Shelley Tworoger•Bo Li
Nature Communications
2024
•2024/9/17
•Vol.15 No.1 p.1-13
T cell senescence alters the homeostasis of distinct T cell populations and results in decayed adaptive immune protection in older individuals, but a link between aging and dynamic T cell clone changes has not been made. Here, using a newly developed computational framework, Repertoire Functional Un...
Clonal selectionComputational biology and bioinformaticsImmunological deficiency syndromesT cells
10.1038/S41467-024-52522-Z
ISSN:2041-1723
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
Shenderov Eugene•De Marzo Angelo M.•Lotan Tamara L.•Wang Hao•Chan Sin等 24 人
Nature Medicine
2023
•2023/4/3
•00 p.1-10
B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular...
ImmunotherapyPhase II trialsProstate cancer
10.1038/S41591-023-02284-W
ISSN:1078-8956
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
David G. Coffey•Francesco Maura•Edgar Gonzalez-Kozlova•J. Javier Diaz-Mejia•Ping Luo等 23 人
Nature Communications
2023
•2023/9/2
•Vol.14 No.1 p.1-12
The role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma (MM) is not well understood. In this study, we comprehensively profile the immune system in patients with newly diagnosed MM receiving continuous lenalidomide maintenance therapy with the aim o...
Cancer microenvironmentCytotoxic T cellsGene regulation in immune cellsMyeloma
10.1038/S41467-023-40966-8
ISSN:2041-1723
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
Corey Smith•Margaret McGrath•Michelle A. Neller•Katherine K. Matthews•Pauline Crooks等 9 人
Npj Precision Oncology
2021
•2021/3/19
•Vol.5 No.1 p.1-5
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major roadblock f...
Cancer immunotherapyTumour virus infections
10.1038/S41698-021-00162-7
ISSN:2397-768X